Pharma companies won't fund research because they don't consider the risk-reward tradeoff worthwhile compared to other options for their resources. Off label

Pharma companies won't fund research because they don't consider the risk-reward tradeoff worthwhile compared to other options for their resources. Off label use in endemic, and it does give a path to play with some things clinically; however if you formed a company around this idea and could have been demonstrated to do it, you'll be pulled off the market so fast it will make your head spin. What you are really talking about is about funding the research that wont work, in the hopes that eventually you hit on something that does. If you do hit on that and can rigorously demonstrate it, market access will not be a problem.